Dexmedetomidine vs Midazolam on Resting Energy Expenditure in Critically Ill Patients
Mechanical Ventilation, Dexmedetomidine, Midazolam
About this trial
This is an interventional treatment trial for Mechanical Ventilation
Eligibility Criteria
Inclusion Criteria:
- The study will be designed to recruit 30 critically-ill patients who will be admitted to the surgical ICU for ventilatory support and will be expected to continue for 2 days or longer.
Exclusion Criteria:
- Age < 18 years old.
- Pregnant patient.
- Serious central nervous system pathologies (traumatic brain injury, acute stroke, uncontrolled seizures).
- Patient who will require fraction of inspired oxygen more than 0.6.
- Air leak from the chest tube.
- Patient with body temperature > 39 Celsius.
- Acute hepatitis or severe liver disease (Child-Pugh class C).
- Left ventricular ejection fraction less than 30%.
- Heart rate less than 50 beats/min.
- Second or third degree heart block.
- Systolic pressure < 90 mmHg despite of infusion of 2 vasopressors.
- Patients with known endocrine dysfunction.
- Patient with hypothermia
- Patient on Positive end expiratory pressure more than 14 cmH2o
Sites / Locations
- Cairo University
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Dexmedetomidine group
midazolam group
Patients will receive analgesia with fentanyl at a fixed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug. Group I patients will have dexmedetomidine (0.075 µg.kg-1.mL-1). Dexmedetomidine infusion will be started at 0.15 µg.kg-1.hr-1 (2 mL.hr-1) and will be adjusted by 0.15 µg.kg-1.h-1 increments to a maximum of 0.75 µg/kg/h (10 ml.h-1) Intervention: indirect calorimetry
Patients will receive analgesia with fentanyl at a fixed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug. Group II patients will have midazolam (0.5 mg.mL-1). Midazolam will be started at 1 mg.h-1 (2 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (10 mL.h-1). All infusions will be adjusted by increments of 2 mL.hr-1 to maintain blinding. Patients in either group not adequately sedated by the maximum infusion rate of the study medication will receive a bolus dose of fentanyl 0.5 µg.kg-1. Intervention: indirect calorimetry